Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Vizimpro?

See the DrugPatentWatch profile for Vizimpro

Vizimpro® is the brand name for the selective serotonin‑reuptake inhibitor (SSRI) fluvoxamine. It’s most commonly prescribed for major depressive disorder (MDD) and obsessive‑compulsive disorder (OCD), and it’s sometimes used off‑label for other anxiety‑related conditions.

What Vizimpro Does

  • Mechanism: Increases serotonin levels in the brain by blocking its reuptake into presynaptic neurons.
  • Therapeutic Uses:
    • Major depressive disorder (adult & pediatric)
    • Obsessive‑compulsive disorder (OCD)
    • Sometimes for panic disorder or other anxiety conditions

Typical Dosage (Adults)

Indication Starting Dose Titration Maintenance Dose
MDD 50 mg once daily (take 3–5 days) Increase to 100 mg daily 100–300 mg daily (max 300 mg)
OCD 50 mg once daily Increase to 100 mg daily 100–300 mg daily
  • Timing: Can be taken with or without food. Some people prefer an evening dose to reduce insomnia.
  • Titration: Usually increased every 1–2 weeks, depending on tolerability and response.
  • Duration: Treatment is typically continued for 6–12 months after symptom remission, and many patients stay on therapy longer to prevent relapse.

Common Side Effects

Symptom Likelihood Management Tips
Nausea, vomiting Common (≈15–30 %) Take with food; consider a pro‑emetic or anti‑emetic if needed
Insomnia Common Take at night; avoid caffeine; sleep hygiene
Dizziness Common Start low; avoid abrupt stopping
Sexual dysfunction (decreased libido, erectile dysfunction, anorgasmia) Common Discuss with prescriber; adjust dose or add a supportive therapy
Dry mouth, constipation Common Hydration, fiber, OTC remedies
Weight changes Variable Monitor weight, diet counseling
Sweating Variable Anticholinergic OTC meds can help
Headache Variable OTC pain relievers (avoid NSAIDs if not recommended)

Note: Most side effects diminish after 4–6 weeks of continuous therapy. If a side effect persists or worsens, consult your provider.

Serious Risks

Risk Description Prevention
Serotonin syndrome Symptoms: agitation, confusion, hyperthermia, muscle rigidity, autonomic instability. Avoid concurrent serotonergic drugs (e.g., MAO‑I, other SSRIs, TCAs, SNRIs, triptans, dextromethorphan).
QT prolongation Fluvoxamine can modestly prolong the QT interval. Avoid with other QT‑prolonging drugs (e.g., certain antipsychotics, antiarrhythmics).
Severe GI bleed Rare, but possible especially if combined with NSAIDs or anticoagulants. Use NSAIDs cautiously, monitor for bleeding.
Allergic reactions Rash, itching, angioedema. Discontinue immediately and seek medical attention.

Drug Interactions

Drug Interaction What to Do
MAO inhibitors (e.g., phenelzine) Serotonin syndrome Never combine
Other SSRIs/SNRIs Increased serotonergic effect Avoid co‑prescribing
St. John’s Wort Serotonin syndrome Avoid
Anticoagulants (warfarin) ↑ bleeding risk Monitor INR, adjust dose
CYP1A2 inducers (e.g., ciprofloxacin, rifampin) ↓ fluvoxamine levels May need dose adjustment
CYP1A2 inhibitors (e.g., fluvoxamine itself, cimetidine) ↑ fluvoxamine levels Monitor for toxicity

Fluvoxamine is a moderate CYP1A2 inhibitor, so it can increase serum levels of drugs metabolized by this enzyme.

Precautions & Contraindications

Population Key Points
Pregnancy Category D in some regions; use only if benefits outweigh risks.
Breastfeeding Fluvoxamine is excreted in breast milk; avoid or discuss with provider.
Pediatrics Approved for OCD in children ≥7 years; dose carefully titrated.
Elderly Higher sensitivity to side effects (e.g., falls, orthostatic hypotension).
Liver/renal impairment Dose may need adjustment; monitor liver enzymes and creatinine.
History of bipolar disorder Risk of inducing mania; monitor mood changes.

How to Take Vizimpro Safely

  1. Follow Prescription: Take exactly as prescribed; do not stop abruptly—discontinuation can cause withdrawal symptoms (dizziness, nausea, “flu‑like” symptoms).
  2. Monitor: Keep a symptom diary, especially in the first 4–6 weeks.
  3. Report: Contact your prescriber if you notice:
    • Severe insomnia or sleep disruption
    • New or worsening depressive or anxious symptoms
    • Signs of serotonin syndrome (e.g., agitation, tremor, fever)
    • Severe GI bleeding (black stools, vomiting blood)
  4. Lifestyle: Combine therapy with regular exercise, balanced diet, and good sleep hygiene to enhance efficacy.
  5. Avoid Alcohol: Can worsen side effects (e.g., dizziness, sedation).

FAQ

Q: How long until I feel better?
A: Most people notice improvement after 4–6 weeks, but full response can take 8–12 weeks.

Q: Can I take it with other antidepressants?
A: Generally no, due to serotonin syndrome risk. Your clinician may consider a switch or a gradual taper of the other agent instead.

Q: Is Vizimpro safe for people on blood thinners?
A: It can slightly increase bleeding risk; monitor INR and discuss with your provider.

Q: Can I drive?
A: If you experience drowsiness or dizziness, avoid driving until you know how the medication affects you.

Bottom Line

Vizimpro (fluvoxamine) is a well‑established SSRI for depression and OCD, with a predictable side‑effect profile and a clear dosing strategy. As with any medication, the key to success is close communication with your prescriber, awareness of potential interactions, and regular monitoring. If you have any specific questions—e.g., how it might interact with a supplement you’re taking, or what to do if you miss a dose—feel free to ask!



Other Questions About Vizimpro :

What are the side effects of Vizimpro? Vizimpro vs tagrisso? Vizimpro discontinued united states 2024? Vizimpro patent expiry 2026? Pfizer vizimpro patent expiration date? Vizimpro patent expiration 2026? Vizimpro price?

AI-Drug Label Prescribing Information Alignment Report

74
74%
Grade C

Partial

Needs Correction

Patient Risk: Moderate

Summary

Overall alignment is generally good with labeling for indication, mechanism, and most dosing/administration details, but there is a contradicted missed-dose instruction (high-risk dosing safety issue) and multiple safety/adverse-effect/interaction details that are not supported by the provided label excerpts.

Category Scores

Indication
92
Excellent
Dosage
70
Partial
Warnings
86
Good
Dosage
70
Partial
Dosage
70
Partial
AdverseReactions
40
Poor
Administration
85
Good

Accurate Statements

Vizimpro is the brand name for dacomitinib.
12.1 Mechanism of Action
Vizimpro is used for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations (as detected by an FDA-approved test).
1 INDICATIONS AND USAGE
Vizimpro is an irreversible EGFR (HER1/EGFR, HER2, HER4 family) inhibitor and targets EGFR activating mutations including exon 19 deletion or exon 21 L858R.
12.1 Mechanism of Action; 1 INDICATIONS AND USAGE
Recommended dose is 45 mg taken orally once daily; can be taken with or without food; take the same time each day.
2.2 Recommended Dosage
Dose reductions include reducing to 30 mg then 15 mg for adverse reactions if needed.
2.3 Dosage Modifications for Adverse Reactions; Table 1
Monitor for pulmonary symptoms indicative of ILD/pneumonitis and withhold VIZIMPRO and promptly investigate; permanently discontinue if ILD is confirmed.
5.1 Interstitial Lung Disease (ILD)
Rash is described in the label as occurring with VIZIMPRO, including Grade 3/4 rash.
5.3 Dermatologic Adverse Reactions
Dacomitinib use requires contraception counseling for females of reproductive potential.
5.4 Embryo-Fetal Toxicity
If a patient vomits or misses a dose, do not take an additional dose or make up the missed dose; continue with the next scheduled dose.
2.2 Recommended Dosage
Avoid concomitant use of PPIs; alternatives include locally-acting antacids or H2-receptor antagonist timing (VIZIMPRO at least 6 hours before or 10 hours after).
2.4 Dosage Modifications for Acid-Reducing Agents; 7.1 Effect of Other Drugs on VIZIMPRO

Unsupported Statements

Common side effects of Vizimpro include diarrhea.
The provided label excerpts do not present a 'common side effects' list; diarrhea is mentioned only in the context of dosage modifications (Table 2).
Common side effects of Vizimpro include mouth sores (stomatitis).
No stomatitis/stomatitis wording in the provided label sections.
Common side effects of Vizimpro include dry skin.
No dry skin wording in the provided label sections.
Common side effects of Vizimpro include nail changes.
No nail changes wording in the provided label sections.
Common side effects of Vizimpro include decreased appetite.
No decreased appetite wording in the provided label sections.
Common side effects of Vizimpro include weight loss.
No weight loss wording in the provided label sections.
Common side effects of Vizimpro include fatigue.
No fatigue wording in the provided label sections.
Serious risks of dacomitinib include liver function changes.
No liver function changes wording in the provided label sections.
Dacomitinib may have possible effects on heart or wound healing.
No heart or wound-healing wording in the provided label sections.
Persistent chest pain while taking dacomitinib is an indication to seek medical attention.
No persistent chest pain counseling wording in the provided label sections.
Yellowing of the skin or eyes while taking dacomitinib is an indication to seek medical attention.
No jaundice/yellowing counseling wording in the provided label sections.
Dark urine while taking dacomitinib is an indication to seek medical attention.
No dark urine counseling wording in the provided label sections.
Dacomitinib interactions include interactions with strong CYP inhibitors.
No CYP inhibitor/inducer detail in the provided label excerpts (7.1/2.4).
Dacomitinib interactions include interactions with strong CYP inducers.
No CYP inhibitor/inducer detail in the provided label excerpts (7.1/2.4).
Avoiding grapefruit is recommended for people taking dacomitinib.
No grapefruit-related wording in the provided label sections.
Dacomitinib is not recommended in pregnancy.
The provided label excerpts describe fetal harm and contraception counseling but do not state 'not recommended in pregnancy.'

Contradictions

High

AI Statement
If a dose of dacomitinib is missed, it should be taken as soon as remembered unless it is nearly time for the next dose.

Label Reference
2.2 Recommended Dosage: If the patient vomits or misses a dose, do not take an additional dose or make up a missed dose but continue with the next scheduled dose.

Important Omissions

Missed-dose instruction should be stated as: do not take an additional dose or make up the missed dose; continue with the next scheduled dose.
Importance: High

Safety Assessment

Potential Patient Risk: Moderate
A directly contradicted missed-dose instruction could result in incorrect additional dosing. Several counseling claims about specific symptoms, adverse effects, and interaction categories are not supported by the provided label excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Needs Correction

Primary Issue
Missed-dose guidance conflicts with the label (should not take an additional or made-up dose).

Suggested Improvement
Replace missed-dose instruction with the label wording: if a patient vomits or misses a dose, do not take an additional dose or make up a missed dose; continue with the next scheduled dose.

Drug Brand Mention Assessment

Branding Score
52
Visibility
56
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

Used to treat certain non-small cell lung cancers (NSCLC) that have activating EGFR mutations.

Core Claims
  • Vizimpro is the brand name for dacomitinib.
  • Used to treat certain non-small cell lung cancers (NSCLC) with activating EGFR mutations.
  • It irreversibly blocks EGFR signaling, helping to slow or stop cancer cell growth.
  • Common side effects include rash and diarrhea.
Differentiators
  • Irreversibly blocks EGFR signaling.
  • Used for NSCLC with activating EGFR mutations (e.g., exon 19 deletions or L858R).
  • Taken as 45 mg once daily by mouth.
Pricing Perception: Not Mentioned